Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,694 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ubiquitin-specific protease 7 inhibitors reveal a differentiated mechanism of p53-driven anti-cancer activity.
Futran AS, Lu T, Amberg-Johnson K, Xu J, Yang X, He S, Boyce S, Bell JA, Pelletier R, Suzuki T, Huang X, Qian H, Fang L, Xing L, Xu Z, Kurtz SE, Tyner JW, Tang W, Guo T, Akinsanya K, Madge D, Jensen KK. Futran AS, et al. Among authors: xing l. iScience. 2024 Apr 9;27(5):109693. doi: 10.1016/j.isci.2024.109693. eCollection 2024 May 17. iScience. 2024. PMID: 38689642 Free PMC article.
Deep learning enables rapid identification of potent DDR1 kinase inhibitors.
Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy VA, Aladinskaya AV, Terentiev VA, Polykovskiy DA, Kuznetsov MD, Asadulaev A, Volkov Y, Zholus A, Shayakhmetov RR, Zhebrak A, Minaeva LI, Zagribelnyy BA, Lee LH, Soll R, Madge D, Xing L, Guo T, Aspuru-Guzik A. Zhavoronkov A, et al. Among authors: xing l. Nat Biotechnol. 2019 Sep;37(9):1038-1040. doi: 10.1038/s41587-019-0224-x. Epub 2019 Sep 2. Nat Biotechnol. 2019. PMID: 31477924
Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors.
Iketani S, Forouhar F, Liu H, Hong SJ, Lin FY, Nair MS, Zask A, Huang Y, Xing L, Stockwell BR, Chavez A, Ho DD. Iketani S, et al. Among authors: xing l. bioRxiv [Preprint]. 2020 Aug 4:2020.08.03.235291. doi: 10.1101/2020.08.03.235291. bioRxiv. 2020. PMID: 32793898 Free PMC article. Updated. Preprint.
Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors.
Iketani S, Forouhar F, Liu H, Hong SJ, Lin FY, Nair MS, Zask A, Huang Y, Xing L, Stockwell BR, Chavez A, Ho DD. Iketani S, et al. Among authors: xing l. Nat Commun. 2021 Apr 1;12(1):2016. doi: 10.1038/s41467-021-22362-2. Nat Commun. 2021. PMID: 33795671 Free PMC article.
Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity.
Resnick SJ, Iketani S, Hong SJ, Zask A, Liu H, Kim S, Melore S, Lin FY, Nair MS, Huang Y, Lee S, Tay NES, Rovis T, Yang HW, Xing L, Stockwell BR, Ho DD, Chavez A. Resnick SJ, et al. Among authors: xing l. J Virol. 2021 Jun 24;95(14):e0237420. doi: 10.1128/JVI.02374-20. Epub 2021 Jun 24. J Virol. 2021. PMID: 33910954 Free PMC article.
The biological roles of CD47 in ovarian cancer progression.
Xing L, Wang Z, Feng Y, Luo H, Dai G, Sang L, Zhang C, Qian J. Xing L, et al. Cancer Immunol Immunother. 2024 Jun 4;73(8):145. doi: 10.1007/s00262-024-03708-3. Cancer Immunol Immunother. 2024. PMID: 38832992 Review.
3,694 results